Independent safety information
Guides, comparisons, and research summaries for people considering, supporting, or researching ibogaine and 5-MeO-DMT experiences in Mexico.
01 / orientation
Plain Compass 74 organizes safety information around the decisions people actually face: what is known, what is uncertain, what should be verified, and what marketing language cannot establish. The main safety brief gives that wider frame before any comparison or checklist is used.
These are information services, not clinical services. Our independent approach and scope explain why the material emphasizes plain language, documented limits, and informed choice.
02 / information offerings
Each entry is designed to support research and discussion, without presenting itself as individualized medical or legal guidance.
Structured explainers outline risk factors, questions to raise, and the difference between a stated protocol and evidence that a safeguard is actually in place. For setting-specific context, see ibogaine treatment considerations in Mexico.
Comparison pages place screening, emergency planning, regulatory uncertainty, and claims of benefit beside one another so they can be evaluated on the same terms. The ibogaine versus ayahuasca comparison is one example of that approach.
Research summaries distinguish early findings, reported experience, and unanswered questions. This matters because U.S. federal health guidance on psychedelic and dissociative drugs notes that these substances can carry important risks and remain an active area of research.
Plain-language definitions help readers recognize when a claim, symptom, or process needs more scrutiny. Context for what ibogaine can feel like and for possible ibogaine aftereffects can make unfamiliar terms easier to discuss carefully.
03 / evidence panel
Ibogaine is a psychoactive alkaloid associated with the ibogaine reference overview; that basic description does not answer whether a particular setting has appropriate screening, monitoring, or escalation plans.
Information about ibogaine and depression-related claims is most useful when it keeps medication history, mental health history, and uncertainty in view rather than treating a label as a conclusion.
Readers comparing regions can use material on ibogaine treatment in Oregon to see how setting, oversight, and stated standards can alter what needs verification.
04 / comparison lens
| Question area | What a clear answer includes | What remains a caution signal |
|---|---|---|
| Screening | Specific discussion of health history, current medicines, and whether concerns change the plan. | Vague assurances that everyone is “cleared” without explaining how. |
| Emergency planning | Who responds, what escalation means, and how transport or urgent care would be handled. | General statements about being “safe” without an operational plan. |
| Evidence claims | A distinction between research, personal reports, and promotional language. | Guaranteed outcomes or a refusal to name limitations. |
| Regulatory context | Plain acknowledgement of uncertainty and the boundaries of the setting. | Claims that legality alone proves safety or quality. |
05 / FAQ
No. Plain Compass 74 is an independent information resource. It does not diagnose, screen, approve, arrange, or provide treatment, and it does not replace professional medical or legal advice.
Comparisons make the basis for a decision visible: evidence limits, screening detail, stated safeguards, and regulatory questions. They are designed to reduce false certainty, not to select a provider or experience for anyone.
It means separating published evidence from anecdote and marketing, naming gaps where they exist, and checking claims against reliable context. For example, the DEA’s ibogaine fact sheet provides one official reference point on the substance’s status and risks, rather than a basis for a personal treatment decision.
Use the brief carefully
Use the guides and comparisons to clarify what needs to be verified, what remains uncertain, and when a claim deserves more careful scrutiny.